Lintzeris N, Bhardwaj A, Mills L, et al. - In this parallel double-blind randomized clinical trial involving 128 candidates (mean [SD] age was 35.0 [10.9] years), researchers tested the safety and effectiveness of nabiximols, a combination of tetrahydrocannabinol and cannabidiol, in the treatment of patients with cannabis dependence who are seeking treatment. For this 12-week, multisite outpatient study, they selected candidates from four outpatient specialist alcohol and drug treatment services in New South Wales, Australia in this trial comparing nabiximols vs placebo. The data presented in this work showed a 12-week course of nabiximols led to significantly fewer days of illicit cannabis use vs placebo, and was well tolerated by candidates with few adverse events.